Biohaven Ltd

BHVN

Company Profile

  • Business description

    Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

  • Contact

    c/o Biohaven Pharmaceuticals, Inc
    215 Church Street
    New HavenCT06510
    USA

    T: +1 203 404-0410

    https://www.biohaven.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    274

Stocks News & Analysis

stocks

ASX healthcare share undervalued post earnings

Short term headwinds mask long term value opportunity.
stocks

ASX energy share sees 363% increase in dividend

Geopolitical tensions drive strong profit and dividends for oil refiner.
stocks

Wide moat share remains cheap despite rising costs

Higher costs weigh on profits but stronger sales trends support long term outlook.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,338.8054.50-0.58%
CAC 408,478.5739.370.47%
DAX 4026,324.3558.210.22%
Dow JONES (US)53,577.40160.240.30%
FTSE 10010,876.369.80-0.09%
HKSE25,652.97141.870.56%
NASDAQ26,151.30171.110.66%
Nikkei 22566,262.16405.730.62%
NZX 50 Index14,013.2120.490.15%
S&P 5007,677.2824.420.32%
S&P/ASX 2009,127.8055.90-0.61%
SSE Composite Index3,912.5223.080.59%

Market Movers